The project is developing an innovative drug for advanced liver disease including non-alcoholic steatohepatitis (NASH) where there are limited existing treatment options. The drug is designed to be administered subcutaneously, selectively target to the liver and increase the expression of a protein in the liver which is down-regulated in disease. Increasing expression of the target protein should both improve the function of normal liver cells impacted by the disease and inhibit the disease itself and thus restore normal liver function. The outcome of the proposed work, if successful, will be a clinical candidate that can be progressed to testing in liver diseases such as NASH as well as a selective delivery platform that can be used with chemically related drugs to treat a range of liver diseases.